[go: up one dir, main page]

WO2003074004A3 - Method of producing antigens - Google Patents

Method of producing antigens Download PDF

Info

Publication number
WO2003074004A3
WO2003074004A3 PCT/US2003/006661 US0306661W WO03074004A3 WO 2003074004 A3 WO2003074004 A3 WO 2003074004A3 US 0306661 W US0306661 W US 0306661W WO 03074004 A3 WO03074004 A3 WO 03074004A3
Authority
WO
WIPO (PCT)
Prior art keywords
producing
antigens
reactive
transglutaminase
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/006661
Other languages
French (fr)
Other versions
WO2003074004A2 (en
Inventor
Szu-Yi Chou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/231,063 external-priority patent/US20030224476A1/en
Priority claimed from US10/231,470 external-priority patent/US7101695B2/en
Priority claimed from US10/231,213 external-priority patent/US20040001848A1/en
Priority claimed from US10/231,298 external-priority patent/US20030219853A1/en
Priority claimed from US10/231,114 external-priority patent/US7485438B2/en
Application filed by Individual filed Critical Individual
Priority to AU2003213718A priority Critical patent/AU2003213718A1/en
Publication of WO2003074004A2 publication Critical patent/WO2003074004A2/en
Anticipated expiration legal-status Critical
Publication of WO2003074004A3 publication Critical patent/WO2003074004A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Embodiments of the invention generally provide methods and compositions for producing polyvalent antigens, disease-specific antigens, transglutaminase-reactive compounds, and recombinant transglutaminases. A method of producing a cross-linked compound by a biological agent is also provided. The invention provides a method for producing a cross-linked antigen and a method of using cross-linked products as antigens to immunize animals and induce strong immune responses. In addition, a method of producing an antigen specific for Alzheimer's disease is provided. Further, a method of producing a polyvalent antigen for two or more diseases is provided. Thus, compositions of antigens are prepared and provided to immunize animals and induce strong immune responses. The invention provides purified recombinant transglutaminases reactive to a broad range of compounds and exhibit broad substrate activity. Additionally, the invention provides a method of attaching one or more amino acid residues to a compound to be reactive with transglutaminase, even for transglutaminase non-reactive compounds.
PCT/US2003/006661 2002-03-01 2003-03-03 Method of producing antigens Ceased WO2003074004A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003213718A AU2003213718A1 (en) 2002-03-01 2003-03-03 Method of producing antigens

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US36116602P 2002-03-01 2002-03-01
US60/361,166 2002-03-01
US36344502P 2002-03-08 2002-03-08
US60/363,445 2002-03-08
US10/231,470 2002-08-28
US10/231,063 US20030224476A1 (en) 2002-03-01 2002-08-28 Method of producing transglutaminase reactive compound
US10/231,298 2002-08-28
US10/231,213 2002-08-28
US10/231,470 US7101695B2 (en) 2002-03-01 2002-08-28 Method of producing transglutaminase having broad substrate activity
US10/231,213 US20040001848A1 (en) 2002-03-01 2002-08-28 Method of producing disease-specific antigens
US10/231,298 US20030219853A1 (en) 2002-03-01 2002-08-28 Method of cross-linking a compound
US10/231,114 US7485438B2 (en) 2002-03-01 2002-08-28 Method of producing polyvalent antigens
US10/231,063 2002-08-28
US10/231,114 2002-08-28

Publications (2)

Publication Number Publication Date
WO2003074004A2 WO2003074004A2 (en) 2003-09-12
WO2003074004A3 true WO2003074004A3 (en) 2006-08-10

Family

ID=27792403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006661 Ceased WO2003074004A2 (en) 2002-03-01 2003-03-03 Method of producing antigens

Country Status (2)

Country Link
AU (1) AU2003213718A1 (en)
WO (1) WO2003074004A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8961544B2 (en) 2010-08-05 2015-02-24 Lifebond Ltd. Dry composition wound dressings and adhesives comprising gelatin and transglutaminase in a cross-linked matrix
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9017664B2 (en) 2006-12-15 2015-04-28 Lifebond Ltd. Gelatin-transglutaminase hemostatic dressings and sealants
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1711208A2 (en) * 2004-01-28 2006-10-18 Curix APS Conjugates of amyloid proteins as vaccines for amyloid-related diseases
TW200726482A (en) * 2005-06-30 2007-07-16 Merck & Co Inc Method for preparing a covalently cross linked oligomer of amyloid beta peptides
PL1976877T5 (en) 2005-11-30 2017-09-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
EP2054436A1 (en) * 2006-08-18 2009-05-06 Novo Nordisk Health Care AG Transglutaminase variants with improved specificity
US20100087371A1 (en) * 2007-02-22 2010-04-08 Sean Hu Transglutaminase Variants with Improved Specificity
WO2009153751A2 (en) * 2008-06-18 2009-12-23 Lifebond Ltd A method for enzymatic cross-linking of a protein
CN102124058B (en) 2008-06-18 2014-05-28 生命连结有限公司 Improved Crosslinking Composition
AU2010334412B2 (en) 2009-12-22 2016-02-04 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544638A (en) * 1984-05-18 1985-10-01 The Regents Of The University Of California Synthesis of cross-links in the helical domain of collagen using pyridoxal 5-phosphate and copper or iron
US6010871A (en) * 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544638A (en) * 1984-05-18 1985-10-01 The Regents Of The University Of California Synthesis of cross-links in the helical domain of collagen using pyridoxal 5-phosphate and copper or iron
US6010871A (en) * 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE JONG G.A.H. ET AL: "Purification and substrate specificity of transglutaminase from blood and Streptoverticillium mobaraense", JOUR. AGRIC FOOD CHEM., vol. 49, 2001, pages 3389 - 3393, XP003001875 *
KAHLEM P. ET AL.: "Peptides containing glutamine repeats as substrates for transglutaminase catalyzed cross-linking: Relevance to diseases of the nervous system", PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 14580 - 14585, XP000918974 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9017664B2 (en) 2006-12-15 2015-04-28 Lifebond Ltd. Gelatin-transglutaminase hemostatic dressings and sealants
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US8961544B2 (en) 2010-08-05 2015-02-24 Lifebond Ltd. Dry composition wound dressings and adhesives comprising gelatin and transglutaminase in a cross-linked matrix

Also Published As

Publication number Publication date
WO2003074004A2 (en) 2003-09-12
AU2003213718A1 (en) 2003-09-16
AU2003213718A8 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
WO2003074004A3 (en) Method of producing antigens
WO2006031560A3 (en) Process for concentration of antibodies and therapeutic products thereof
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
EP1373301A4 (en) Reducing the immunogenicity of fusion proteins
CA2290485A1 (en) Method for the production of non-immunogenic proteins
WO2002020569A3 (en) Mammalian genes; related reagents and methods
WO2003017935A3 (en) Human antibodies specific for interleukin 15 (il-15)
WO2004043407A3 (en) Methods and products for treating staphylococcal infections
WO2000053758A3 (en) Compositions and methods for the treatment of immune related diseases
MXPA05007211A (en) A pharmaceutical composition comprising an immunoglobulin fc region as a carrier.
EP2292664A3 (en) Multispecific deimmunized CD3-binders
WO2004076620A3 (en) Human antibodies specific for interleukin 15 (il-15)
DE602005001445D1 (en) N-TERMINAL MONOPEGYLATED HUMAN GROWTH HORMONE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE
WO2010044889A3 (en) Torque teno virus (ttv) isolates and compositions
WO2012075173A3 (en) Compositions and method for deimmunization of proteins
ATE321859T1 (en) B2MICROGLOBULIN FUSION PROTEINS AND VARIANTS WITH HIGH AFFINITY
WO2000073452A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002012899A3 (en) Peptides presented by cells
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
WO2002044737A3 (en) Diagnostic and therapeutic compositions and methods related to anaphylatoxin c3a receptor
WO2005121178A3 (en) Immunoaffinity chromatography polyol-responsive monoclonal antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP